Advanced analytical approaches for endocannabinoids and endocannabinoid-like substances: Applications in liver disease research.

Authors

Jun-Yi Zhou, Yan-Qing Chen, Hai-Yu Zhao, Jian-Bo Wan

Published in

Journal of pharmaceutical analysis. Volume 16. Issue 8. Pages 101546. Epub Jan 05, 2026.

Abstract

Endocannabinoids (eCBs) and eCB-like substances are lipid mediators that play vital roles in regulating diverse physiological and pathological processes. These effects are predominantly mediated through interactions with cannabinoid receptors (CBRs), particularly CB1R and CB2R. Due to their typically low abundance in biological samples, the development of precise and efficient analytical methods is essential for accurate quantification of eCBs. The liver serves as a critical site of eCB activity, where dysregulation of eCB levels has been associated with various liver diseases. This review focuses on recent advancements in sample preparation and analytical techniques for eCBs and eCB-like substances from 2017 to 2024, providing a comprehensive evaluation of their strengths and limitations. Additionally, the roles of eCBs in liver lipid metabolism and their involvement in pathological processes are explored in detail. eCBs and eCB-like substances hold promise as diagnostic biomarkers, offering significant potential for applications in both basic research and clinical practice.

PMID:
42604040
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.